302 patents
Page 2 of 16
Utility
PCSK9 Inhibitors and Methods of Treatment Using Same
9 Nov 23
The present disclosure provides dosages and methods for treating a disease associated with proprotein convertase subtilisin/kexin type 9 (PCSK9).
Tina RYDÉN-BERGSTEN, Dinko REKIC, Catarina NILSSON, Jane KNÖCHEL
Filed: 16 Sep 21
Utility
Spirocyclic Compounds
9 Nov 23
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof.
JAMES MICHAEL SMITH, GRAEME RICHARD ROBB, PIOTR ANTONI RAUBO, BERNARD CHRISTOPHE BARLAAM, IAIN ALEXANDER CUMMING
Filed: 15 Jun 23
Utility
Pharmaceutical Compositions Comprising an Antisense Oligonucleotide for Oral Administration
9 Nov 23
A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating.
Anna TIVESTEN, Nigel DAVIES, Marie ELEBRING, Peter GENNEMARK, Mariagrazia MARUCCI, Niclas CLEMMENSEN, Hanna MATIC, Okky PUTRA, Pratik Pankaj UPADHYAY, Katrin WALTER, Lloyd TILLMAN, Luis DELLAMARY, Andreas RÅDEVIK
Filed: 16 Sep 21
Utility
Atr Inhibitors for the Treatment of Cancer
2 Nov 23
This specification discloses the use of an ATR inhibitor, preferably in combination with a taxane, for the treatment of cancer in a particular subset of patients who have previously received immunotherapy.
Simon Andrew SMITH, Emma Jane DEAN, Glen CLACK, Jeeyun LEE
Filed: 10 May 21
Utility
Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors
2 Nov 23
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
GORDON MOODY, MARIA LETIZIA GIARDINO TORCHIA, MICHAEL GLEN OVERSTREET, RYAN GILBRETH
Filed: 23 Apr 21
Utility
Compounds and Their Use
2 Nov 23
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein.
Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM, Giulia Bergonzini, Henrik Graden, Lars Johan Andreas Ulander
Filed: 22 Feb 23
Utility
Methods for Treating Severe Asthma In Patients with Nasal Polyposis
2 Nov 23
Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
MARIA ESTHER GARCIA GIL, JAMES ZANGRILLI, ANNE BURDEN, JAMES KREINDLER
Filed: 27 Mar 23
Utility
Methods of Improving Protein Expression
26 Oct 23
The present disclosure relates to nucleic acids that comprise a nucleotide sequence encoding an immunoglobulin heavy chain, wherein the nucleotide sequences of at one or two introns in the immunoglobulin heavy chain are deleted.
Emma KELSALL, Suzanne GIBSON, Diane HATTON
Filed: 2 Jul 21
Utility
Compositions and Methods for Improved Site-specific Modification
26 Oct 23
The present disclosure provides proteins, compositions, methods, and kits for improved gene editing efficiency.
MARCELLO MARESCA
Filed: 7 Apr 21
Utility
Chemical compounds
24 Oct 23
Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Avipsa Ghosh, Xiaolan Zheng, Martin Packer, Sebastien Louis Degorce
Filed: 22 Jun 21
Utility
Methods of Treating Cancer
19 Oct 23
Kris SACHSENMEIER, Benjamin SIDDERS, Robert D. MULLA, Natalya MARKUZON
Filed: 25 Nov 20
Utility
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
5 Oct 23
Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
Filed: 12 Jun 23
Utility
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
3 Oct 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
Filed: 9 Sep 22
Utility
BINDING MOLECULES AGAINST FRa
21 Sep 23
The present invention provides binding molecules (e.g. antibodies or antigen-binding fragments thereof) against FRα and related antibody-drug conjugates, along with pharmaceutical compositions and kits comprising the same.
Neki PATEL, Roger DODD, Christopher WARD, Paula FRAENKEL, Jorge ZERON-MEDINA CUAIRAN, Frances NEAL
Filed: 2 Mar 23
Utility
Protein kinase B inhibitors
19 Sep 23
Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Filed: 16 Dec 21
Utility
Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
14 Sep 23
Bernard Christophe BARLAAM, Kurt Gordon PIKE, Andrew John EATHERTON, Thomas Anthony HUNT
Filed: 21 Feb 23
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
7 Sep 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 9 Sep 22
Utility
Methods for Generating Primary Immune Cells
7 Sep 23
The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy.
DEEPALI MALHOTRA, MICHAEL OVERSTREET, GORDON MOODY, MARK COBBOLD
Filed: 23 Aug 22
Utility
Amino-triazolopyridine compounds and their use in treating cancer
5 Sep 23
Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
Filed: 27 Aug 21
Utility
5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE Compounds for Use Against Cancer
31 Aug 23
Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof.
Giles Albert Brown, Christine Mary Richardson, Miles Stuart Congreve, Rebecca Paul, Stephen Philippe Andrews, Jonathan Stephen Mason
Filed: 25 Mar 21